Abstract
On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.
Original language | English |
---|---|
Article number | e1115641 |
Journal | OncoImmunology |
Volume | 5 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2016 |
Keywords
- Granulocyte macrophage colony-stimulating factor
- Imlygic®
- OPTiM
- OncoVEX
- T-vec
- talimogene laherparepvec